Screener
Rigel Pharmaceuticals RIGL Single reportable segment — Interest Income (Expense), Operating
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNet.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Commercial related expenses | 7,040 | 5,339 |
| Outside clinical trial related expenses | 6,927 | 4,371 |
| Cost of product sales | 4,606 | 4,409 |
| Consultants and third-party services | 4,006 | 3,409 |
| Other segment items | 3,352 | 3,494 |
| Interest expense, net | 228 | 1,262 |
| Provision for income taxes | 3,003 | 65 |
| Segment income | $8,654 | $11,446 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's single reportable segment — interest income (expense), operating?
- Rigel Pharmaceuticals (RIGL) reported single reportable segment — interest income (expense), operating of -$228K in Q1 2026.
- What does single reportable segment — interest income (expense), operating mean?
- Reflects the net interest income or expense generated from the segment's operating activities, such as cash management or financing arrangements. It provides insight into the segment's financial leverage and capital structure efficiency.
Ask your AI about Rigel Pharmaceuticals's single reportable segment — interest income (expense), operating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude